Alfasigma S.p.A.

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Alfasigma S.p.A. sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 4 completed early-phase tilt upper quartile by trial count

Alfasigma S.p.A.: 7 sponsored US clinical trials, none currently recruiting.

Alfasigma S.p.A. sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Papulopustular Rosacea, with 1 trials.

Upper-quartile sponsor footprint

Alfasigma S.p.A. sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

NCT02914535
COMPLETED Phase 2

Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

NCT05150587
TERMINATED Phase 1

Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas

NCT03188328
COMPLETED Phase 3

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

NCT03025308
TERMINATED Phase 2

Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis

NCT02376972
COMPLETED Phase 1

Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

NCT01467726
COMPLETED Phase 2

Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

NCT00391820

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 2

Therapeutic Areas

Papulopustular Rosacea 1
Ulcerative Colitis 1

How the Alfasigma S.p.A. early-phase archive is shaped

7 indexed studies, none listed as recruiting (0% open); 4 completed (57%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Papulopustular Rosacea (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Alfasigma S.p.A.: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Alfasigma S.p.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Alfasigma S.p.A.3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
Alfasigma S.p.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Alfasigma S.p.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Alfasigma S.p.A. page

7 registered trials is a research-attention snapshot, not an endorsement of Alfasigma S.p.A. or any single study.

  • None of Alfasigma S.p.A.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Papulopustular Rosacea is the condition Alfasigma S.p.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Papulopustular Rosacea trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Alfasigma S.p.A. pipeline card: 7 registered trials from official public datasets.Report a data error.